** Shares of therapy developer Prothena Corporation PRTA.O are down nearly 2% at $4.77 in pre-market trading
** Jefferies downgrades the stock's rating to "hold" from "buy"; slashes PT to $6 from $32, a 8.8% discount to the last close
** PRTA becomes stock with lowest PT, per Jefferies, on Wall Street
** We see uncertainty around the pipeline given the failure of the AL amyloidosis (a disease where abnormal proteins damage organs) drug - brokerage
** Adds it finds "risk" in the co's Alzheimer's drug PRX012 phase 1 trial data
** Co says phase 3 clinical trial of Birtamimab in patients with AL amyloidosis did not meet primary endpoint
** Avg rating of 10 analysts is "buy"; median PT $29.5— data compiled by LSEG
** PRTA falls ~52.49% YTD, up to last close
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。